HER-2 binding antibodies

US12129307B2 · kind B2 · utility

Assignee

• MAB Discovery GmbH · DE

Inventors

• Stephan Fischer · Weilheim, DE
• Michael Brandt · Iffeldorf, DE

Key dates

• Filing date: Jul 14, 2021
• Grant date: Oct 29, 2024
• Expiry date: Jan 29, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/73
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Monoclonal antibodies that specifically bind to HER2, or a fragment or derivative thereof or a polypeptide that contains at least a portion of said antibody that is sufficient to confer specific HER2 binding to the polypeptide. Said antibodies bind to the human Fc receptor and induce FcR mediated signaling pathways. The antibodies according to the invention bind to a different epitope than trastuzumab. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody.